Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qyuns Therapeutics CoHKSE:02509 -1.84%9 Days Payable is 318.05 as of Dec. 2025, which is 30% below its 10-year median of 455.36. GuruFocus rates HKSE:02509 with a GF Score™ of 9/100. The stock has 5 warning signs investors should review. Among 703 Biotechnology companies, Qyuns Therapeutics Co ranks better than 76.96% on this metric.
Qyuns Therapeutics Co Days Payable Historical Data
* Premium members only.
The historical data trend for Qyuns Therapeutics Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02509 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Qyuns Therapeutics Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qyuns Therapeutics Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Qyuns Therapeutics Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Qyuns Therapeutics Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Qyuns Therapeutics Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qyuns Therapeutics Co (HKSE:02509) has a Days Payable of 318.05 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Qyuns Therapeutics Co and its competitors. This is 30% below median its historical median of 455.36. Over the past decade, Qyuns Therapeutics Co's Days Payable has ranged from 402.05 to 508.66. According to the industry distribution chart, Qyuns Therapeutics Co ranks #162 out of 703 companies in the Biotechnology industry, placing it in the top 23%.
Is Qyuns Therapeutics Co's Days Payable too high?
Qyuns Therapeutics Co's current Days Payable of 318.05 is 30% below median its 10-year median of 455.36. Over the past 10 years, this metric has ranged from a low of 402.05 to a high of 508.66. The Biotechnology industry median Days Payable is 112.39. Qyuns Therapeutics Co's value of 318.05 is 183% above this industry median. Based on the distribution chart, Qyuns Therapeutics Co ranks #162 out of 703 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Qyuns Therapeutics Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Qyuns Therapeutics Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Qyuns Therapeutics Co ranks #162 out of 703 companies for Days Payable. This places Qyuns Therapeutics Co in the top 23% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.39. Qyuns Therapeutics Co's value of 318.05 is 183% above this benchmark. Historically, Qyuns Therapeutics Co's own Days Payable has ranged from 402.05 to 508.66 over the past decade. While the company's 10-year median is 455.36 vs. the industry median of 112.39, Qyuns Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.39, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qyuns Therapeutics Co's current Days Payable of 318.05 is 183% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Qyuns Therapeutics Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qyuns Therapeutics Co's current Days Payable is 318.05, which is 30% below median its own 10-year median of 455.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qyuns Therapeutics Co stock overvalued right now?
Qyuns Therapeutics Co (HKSE:02509) has a current Days Payable of 318.05. The current Days Payable is 318.05, which is 30% below median its 10-year median of 455.36 and 183% above the Biotechnology industry median of 112.39. Qyuns Therapeutics Co's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Qyuns Therapeutics Co (HKSE:02509), the current Days Payable is 318.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score
Get the complete analysis for HKSE:02509
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02509 has been successfully added to your 
